Clinical trial
A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment
NCT01437657 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2011
- Completion date
- September 30, 2013
- Enrollment
- 319 (actual)
- Sites
- 76
Conditions
As the registry lists them; a condition with its own page is linked.